These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 7880762)

  • 1. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
    George SA; Ferguson J
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
    Calzavara-Pinton P; Ortel B; Carlino A; Honigsmann H; De Panfilis G
    Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.
    Aubin F; Makki S; Humbert P; Muret P; Agache P
    Arch Dermatol Res; 1994; 286(1):30-4. PubMed ID: 8141609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
    Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
    Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A; Ortel B; Rappersberger K; Hönigsmann H
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis.
    Hofer A; Fink-Puches R; Kerl H; Quehenberger F; Wolf P
    Photodermatol Photoimmunol Photomed; 2006 Feb; 22(1):1-5. PubMed ID: 16436174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
    Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
    Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of 8-methoxypsoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy.
    Bonnot D; Béani JC; Boitard M; Reymond JL; Bériel H; Amblard P
    Photodermatol Photoimmunol Photomed; 1994 Feb; 10(1):33-7. PubMed ID: 8180098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of 8-methoxypsoralen after topical paint PUVA.
    Pham CT; Koo JY
    J Am Acad Dermatol; 1993 Mar; 28(3):460-6. PubMed ID: 8445063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP/5-MOP.
    Langner A; Wolska H; Kowalski J; Duralska H; Murawska E
    Int J Dermatol; 1976 Nov; 15(9):688-9. PubMed ID: 977210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis.
    Collins P; Rogers S
    Br J Dermatol; 1992 Oct; 127(4):392-5. PubMed ID: 1419760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis from 5-methoxypsoralen occurring in a patient with previous flucloxacillin hepatitis.
    Stephens RB; Cooper A
    Australas J Dermatol; 1999 Nov; 40(4):217-9. PubMed ID: 10570561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.
    McNeely W; Goa KL
    Drugs; 1998 Oct; 56(4):667-90. PubMed ID: 9806110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses.
    Engin B; Oguz O
    Int J Dermatol; 2005 Apr; 44(4):337-9. PubMed ID: 15811091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis.
    Vongthongsri R; Konschitzky R; Seeber A; Treitl C; Hönigsmann H; Tanew A
    J Am Acad Dermatol; 2006 Oct; 55(4):627-31. PubMed ID: 17010742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.
    Hannuksela-Svahn A; Pukkala E; Koulu L; Jansén CT; Karvonen J
    J Am Acad Dermatol; 1999 May; 40(5 Pt 1):694-6. PubMed ID: 10321595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.